IP Library Granted Patent US 10,472,349
Granted Patent B2
US 10,472,349 · App. 16/083,209 · Granted Nov 12, 2019

Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof

Inventors: Huibing Luo (Shanghai, CN); Huayong Zhou (Shanghai, CN)
Assignee: SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECH CO
C07D401/14A61K31/506A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,472,349
App. No.
16/083,209
Granted
Nov 12, 2019
Kind
B2
Abstract

A mesylate salt of the compound of formula (I), the preparation method thereof, a pharmaceutical composition containing said salt and the use of said salt in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancers, in mammal, in particular human. The mesylate salt of the compound of formula (I) has a high bioavailability in animal, and can remarkably inhibit the growth of transplanted tumors in animal and show a good safety.

Claims (6)

1. A mesylate salt of the compound of formula (I),

2. A method for preparing the mesylate salt of the compound of formula (I) according to claim 1 , wherein, in a solvent, the compound of formula (I) and methanesulfonic acid are directly reacted to give the mesylate salt.

3. The method according to claim 2 , wherein said solvent is a mixed solvent of acetone and water.

4. A pharmaceutical composition comprising: the mesylate salt of the compound of formula (I) according to claim 1 ; and a pharmaceutically acceptable carrier.

5. A method of treating a patient suffering from cancers, the method comprising administering to the patient the mesylate salt of the compound of formula (I) according to claim 1 .

6. A method of treating a patient suffering from cancers, the method comprising administering to the patient the pharmaceutical composition according to claim 4 .

Assignments (5)
CHANGE OF ADDRESS Recorded May 23, 2023
From: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.
To: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.
Reel/Frame 063725/0223 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGN ADDRESS PREVIOUSLY RECORDED AT REEL: 053403 FRAME: 0900. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 27, 2022
From: SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECHNOLOGY CORPORATIONS
To: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.
Reel/Frame 058876/0435 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 052555 FRAME 0632. ASSIGNOR(S) HEREBY CONFIRMS THE THE ENTIRE RIGHTS AND INTEREST.. Recorded Jun 11, 2020
From: SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECHNOLOGY CORPORATIONS
To: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.
Reel/Frame 053403/0900 →
CHANGE OF NAME Recorded May 1, 2020
From: SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECHNOLOGY CORPORATIONS
To: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.
Reel/Frame 052555/0632 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: LUO, HUIBING; ZHOU, HUAYONG
To: SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECHNOLOGY CORPORATIONS
Reel/Frame 050102/0932 →
Priority Claims (1)
CN 2016 1 0126987 · Mar 7, 2016 · national
Continuity (1)
Related Publication 20190100509A1 · Apr 4, 2019